Clinical reference Biomarker Directory
Back to directory

PROC

Established

Protein C deficiency is a thrombophilia; starting warfarin without heparin overlap risks warfarin-induced skin necrosis.

Also known as Protein C
In plain language

Protein C helps put the brakes on blood clotting. People with too little of it clot more easily, and there's a specific danger: starting the blood thinner warfarin without overlapping it with another blood thinner first can actually cause a serious skin reaction in these patients.

Biomarker & context

PROC encodes Protein C, a natural anticoagulant that, along with Protein S, helps regulate and limit blood clot formation; deficiency increases the risk of venous thromboembolism.

What it indicates

Low Protein C activity supports a diagnosis of hereditary Protein C deficiency, a thrombophilia; severe homozygous deficiency in newborns causes purpura fulminans, a life-threatening clotting emergency requiring immediate treatment.

Diagnosis & clinical testing

Measured via functional clotting assay; testing is best performed away from acute clotting events and anticoagulant therapy, both of which can distort results, similar to other thrombophilia markers discussed earlier.

Guiding treatment

A clinically important interaction: starting warfarin without adequate heparin overlap in a Protein C-deficient patient can trigger warfarin-induced skin necrosis, since Protein C's own short half-life makes it drop before warfarin's anticoagulant effect on other factors takes hold — which is why heparin bridging is standard practice when starting warfarin in these patients.

Clinical significance

Severe homozygous deficiency causes purpura fulminans, a life-threatening neonatal clotting emergency.

References
  1. General hematology reference literature on Protein C deficiency and warfarin-induced skin necrosis.